ArticleChild and adolescent psychiatry and mental health2020
Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists.
Article in Child and adolescent psychiatry and mental health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Symptom network between problematic smartphone use and poor sleep quality in adolescents with depression.BMC psychiatry · 2025Article
- Images: Pharmacological treatment of pediatric insomnia: a successful trial of doxepin.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Quetiapine and Paediatric Psychiatrica:Psychopharmacology bulletin · 2025Review
- Medical practitioners' experiences and considerations when managing sleep medication for adolescents and young adults.Scandinavian journal of primary health care · 2025Article
- The Pathogenesis and Treatment of Insomnia Combined with Depression.International journal of general medicine · 2025Review
- Addressing Sleep Disorders in Psychiatry: Comparing the Use of Melatonin, Trazodone, and Doxepin.Cureus · 2024Article
- Article
- [Overview of chronobiological and sleep medical aspects of depression in adolescents].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024Review
- Pharmacological management of pediatric insomnia.Frontiers in sleep · 2024Review
- The investigation of relationship between serum melatonin levels with Beck Depression Inventory and Beck Scale for Suicidal Ideation in suicide patients.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Poor Sleep Quality in Aging: The Association with Mental Health.International journal of environmental research and public health · 2023Article
- Common Issues for General Practitioners in the Medical Management of Child and Adolescent Psychiatric Care.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Article
- Diagnosis and management of sleep disorders in Prader-Willi syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Review
- Understanding patient characteristics and medication prescriptions in children with mental health and neurodevelopmental disorders referred to a sleep clinic-A quality improvement/quality assurance analysis.Frontiers in psychiatry · 2022Article
- Trazodone Prescribing for Children With Attention Deficit Hyperactivity Disorder on Medicaid in Oregon.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary care physicians and child and adolescent psychiatrists often treat sleep disturbances in children and adolescents with mood disorders using medications off-label, in the absence of clear evidence for efficacy, tolerability and short or long-term safety. This study is the first to report Canadian data about prescribing preferences and perceived effectiveness reported by child and adolescent psychiatrists regarding medications used to manage sleep disturbances in children and adolescents with depression.
methodsCanadian child and adolescent psychiatrists were surveyed on their perception of effectiveness of a range of medications commonly prescribed for sleep disturbances, their ranked preferences for these medications, reasons for avoiding certain medications, and perceived side effects.
resultsSixty-seven active child and adolescent psychiatrists completed the survey. Respondents reported noting significant sleep issues in 40% of all their patients. Melatonin and trazodone were identified as the first treatment of choice by 83% and 10% of respondents respectively, and trazodone was identified as the second treatment of choice by 56% of respondents for treating sleep disturbances in children and adolescents with depression. Melatonin (97%), trazodone (81%), and quetiapine (73%) were rated by a majority of respondents as effective. Doxepin, zaleplon, tricyclic antidepressants, zolpidem, or lorazepam were rarely prescribed due to lack of evidence and/or concerns about adverse effects, long-term safety, suitability for youth, suicidality, and dependence/tolerance.
conclusionsMelatonin and certain off-label psychotropic drugs are perceived as being more effective and appropriate to address sleep disturbances in children and adolescents with depression. More empirical evidence on the efficacy, tolerability and indications for using these medications and newer group of sleep medications in this population is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.